🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  2. RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe, RO4893594

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  3. RO4893594, RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe

    Hoffmann-La Roche

    Neovascular age-related macular degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  4. RO5541267

    Hoffmann-La Roche

    Cohort A: • Metastatic non-small cell lung carcinoma (mNSCLC) • Extensive-stage small-cell lung carcinoma (ES-SCLC) • Advanced or unresectable hepatocellular carcinoma (HCC) Cohort B: • Resected Stage IIB-IIIB (early-stage; per the UICC/AJCC staging system, 8th edition) non-small cell lung carcinoma (NSCLC)

    phase 3 small molecule active

    1 trial

  5. RO7046015, Placebo Prasinezumab

    Hoffmann-La Roche

    Early-Stage Parkinson’s Disease (PD)

    phase 3 small molecule active

    1 trial

  6. RO7435846, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, PEMETREXED, Budenofalk 3mg magensaftresistente Hartkapseln, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT D

    Hoffmann-La Roche

    Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. ROSUVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  8. ROSUVASTATIN, ROSUVASTATIN, INCLISIRAN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN

    Novartis Pharmaceuticals

    Non-obstructive Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  9. Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in Fertigspritze Tollwutvirus (inaktiviert, Stamm Flury LEP)

    The George Institute

    Rabies

    phase 3 small molecule active

    1 trial

  10. Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in Fertigspritze Tollwutvirus (inaktiviert, Stamm Flury LEP)

    The George Institute

    Rabies infection/prophylaxis

    phase 3 small molecule active

    1 trial

  11. Rabipur poeder en oplosmiddel voor oplossing voor injectie in een voorgevulde spuit.Rabiësvaccin (geïnactiveerd).

    The George Institute

    Rabies

    phase 3 small molecule active

    1 trial

  12. Ranibizumab

    Hoffmann-La Roche

    Neovascular Age-related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  13. Ranibizumab

    Regeneron UK Limited

    Macular Degeneration

    phase 3 small molecule completed

    2 trials

  14. Ravulizumab

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  15. Reagila 1.5 mg hard capsules, For the purpose of the clinical study a placebo formulation was prepared using the same white hard gelatine capsule shell., Reagila 3 mg hard capsules, Cariprazine 0.5 mg capsules, hard, Reagila 4.5 mg hard capsules

    Gedeon Richter Plc.

    Adolescent Patients (13 to 17 years of age) with Schizophrenia

    phase 3 small molecule active

    1 trial

  16. Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection

    Celgene Europe Limited

    Myelodysplastic syndrome

    phase 3 small molecule active

    1 trial

  17. Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection

    Celgene Europe Limited

    myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibrosis (MF)

    phase 3 small molecule active

    1 trial

  18. Recombinant Human VEGF Receptor-Fc Fusion Protein

    Biotech Pharmaceutical Co.,

    Neovascular Age-related Macular Degeneration

    phase 3 mab completed

    1 trial

  19. Recombinant human luteinizing hormone (r-hLH)

    Merck KGaA, Darmstadt, Germany

    Hypogonadism

    phase 3 small molecule completed

    1 trial

  20. Recovery Management Checkups (RMC)

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 3 other completed

    1 trial

  21. Regorafenib

    United Therapeutics Europe Ltd

    Gastro-Oesophageal Cancer

    phase 3 small molecule active

    1 trial

  22. Remifentanil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Analgesia

    phase 3 small molecule active

    1 trial

  23. Remimazolam Besylate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Analgesia

    phase 3 small molecule active

    1 trial

  24. Reslizumab

    Teva Generics B.V

    Eosinophilic Asthma

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources